Formibactin A - Flightpath Biosciences
Alternative Names: FP-530Latest Information Update: 09 Jan 2026
At a glance
- Originator Northeastern University
- Developer Flightpath Biosciences
- Class Small molecules
- Mechanism of Action Peptide deformylase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Bacterial vaginosis; Colorectal cancer; Lyme disease; Periodontal disorders